{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:18:09Z","timestamp":1792001889296,"version":"4.4.0"},"reference-count":86,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T00:00:00Z","timestamp":1573084800000},"content-version":"vor","delay-in-days":1651,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1093\/annonc\/mdu527","type":"journal-article","created":{"date-parts":[[2014,11,20]],"date-time":"2014-11-20T06:57:07Z","timestamp":1416466627000},"page":"838-847","source":"Crossref","is-referenced-by-count":21,"title":["Available evidence and new biological perspectives on medical treatment of advanced thymic epithelial tumors"],"prefix":"10.1016","volume":"26","author":[{"given":"D.","family":"Serpico","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Trama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.R.","family":"Haspinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Agustoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Botta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Berardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Palmieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Zucali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Gallucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Broggini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Gatta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Pastorino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Pelosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"de Braud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.C.","family":"Garassino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdu527_bb0010","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.ejca.2012.02.047","article-title":"Rare thoracic cancers, including peritoneum mesotelioma","volume":"48","author":"Siesling","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdu527_bb0015","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1016\/j.ejca.2011.08.008","article-title":"Rare cancers are not so rare: the burden of rare cancers in Europe","volume":"47","author":"Gatta","year":"2011","journal-title":"Eur J Cancer"},{"issue":"10 Suppl 4","key":"10.1093\/annonc\/mdu527_bb0020","doi-asserted-by":"crossref","first-page":"S260","DOI":"10.1097\/JTO.0b013e3181f1f62d","article-title":"Epidemiology of thymoma and associated malignancies","volume":"5","author":"Engels","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1093\/annonc\/mdu527_bb0025","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/JTO.0b013e318276241c","article-title":"Thymoma. A population-based study of the management and outcomes for the province of British Columbia","volume":"8","author":"Mariano","year":"2013","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdu527_bb0030","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ejca.2007.11.004","article-title":"Thymic epithelial tumours: a population-based study of the incidence, diagnostic procedures and therapy","volume":"44","author":"de Jong","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdu527_bb0035","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1002\/1097-0142(19811201)48:11<2485::AID-CNCR2820481123>3.0.CO;2-R","article-title":"Follow-up study of thymomas with special reference to their clinical stages","volume":"48","author":"Masaoka","year":"1981","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdu527_bb0040","series-title":"WHO International Histological Classification of Tumors","first-page":"5","article-title":"Histological typing of tumors of the thymus","author":"Rosai","year":"1999"},{"issue":"3","key":"10.1093\/annonc\/mdu527_bb0045","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.lungcan.2003.12.010","article-title":"Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report","volume":"44","author":"Kim","year":"2004","journal-title":"Lung Cancer"},{"key":"10.1093\/annonc\/mdu527_bb0050","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/00000421-199308000-00014","article-title":"EST 2582 phase II trial of cisplatin in metastatic or recurrent thymoma","volume":"16","author":"Bonomi","year":"1993","journal-title":"Am J Clin Oncol"},{"key":"10.1093\/annonc\/mdu527_bb0055","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1200\/JCO.1999.17.9.2737","article-title":"Treatment of invasive thymoma with single-agent ifosfamide","volume":"17","author":"Highley","year":"1999","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"10.1093\/annonc\/mdu527_bb0060","first-page":"383s","article-title":"A phase II trial of pemetrexed in patients with recurrent thymoma or thymic carcinoma","volume":"24","author":"Loehrer","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu527_bb0065","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/1097-0142(19910701)68:1<30::AID-CNCR2820680106>3.0.CO;2-4","article-title":"Chemotherapy for invasive thymoma: a 13-year experience","volume":"68","author":"Fornasiero","year":"1991","journal-title":"Cancer"},{"issue":"3","key":"10.1093\/annonc\/mdu527_bb0070","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0022-5223(19)34092-9","article-title":"Chemotherapy and operation for invasive thymoma","volume":"106","author":"Rea","year":"1993","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1093\/annonc\/mdu527_bb0075","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/00000421-200206000-00012","article-title":"Chemotherapy for advanced thymic carcinoma: clinical response to cisplatin, doxorubicin, vincristine, and cyclophosphamide (ADOC chemotherapy)","volume":"25","author":"Koizumi","year":"2002","journal-title":"Am J Clin Oncol"},{"issue":"5","key":"10.1093\/annonc\/mdu527_bb0080","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/sj.bjc.6690773","article-title":"Primary chemotherapy with adriamycin, cisplatin, vincristine and cyclophosphamide in locally advanced thymomas: a single institution experience","volume":"81","author":"Berruti","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdu527_bb0085","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1200\/JCO.1994.12.6.1164","article-title":"Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial\u2014the Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group","volume":"12","author":"Loehrer","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu527_bb0090","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.1997.15.9.3093","article-title":"Chemotherapy of invasive thymoma","volume":"15","author":"Loehrer","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu527_bb0095","doi-asserted-by":"crossref","first-page":"100","DOI":"10.7326\/0003-4819-129-2-199807150-00006","article-title":"A multidisciplinary approach to therapy for unresectablemalignant thymoma","volume":"129","author":"Shin","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1093\/annonc\/mdu527_bb0100","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/JTO.0b013e31802bafc8","article-title":"Multimodality treatment for advanced invasive thymoma with cisplatin, doxorubicin, and methylprednisolone","volume":"2","author":"Yokoi","year":"2007","journal-title":"J Thorac Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdu527_bb0105","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/1097-0142(19910815)68:4<706::AID-CNCR2820680407>3.0.CO;2-H","article-title":"Neoadjuvant chemotherapy, surgery, and postoperative radiation therapy for invasive thymoma","volume":"68","author":"Macchiarini","year":"1991","journal-title":"Cancer"},{"issue":"6","key":"10.1093\/annonc\/mdu527_bb0110","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/j.athoracsur.2004.12.047","article-title":"Advanced stage thymomas and thymic carcinomas: results of multimodality treatments","volume":"79","author":"Lucchi","year":"2005","journal-title":"Ann Thorac Surg"},{"key":"10.1093\/annonc\/mdu527_bb0115","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1200\/JCO.1996.14.3.814","article-title":"Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group","volume":"14","author":"Giaccone","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu527_bb0120","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1245\/s10434-010-1134-9","article-title":"New predictors of response to neoadjuvant chemotherapy and survival for invasive thymoma: a retrospective analysis","volume":"17","author":"Mineo","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"10.1093\/annonc\/mdu527_bb0125","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1002\/1097-0142(20010601)91:11<2010::AID-CNCR1226>3.0.CO;2-2","article-title":"Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial","volume":"91","author":"Loehrer","year":"2001","journal-title":"Cancer"},{"issue":"6","key":"10.1093\/annonc\/mdu527_bb0130","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1097\/JTO.0b013e3181db3dee","article-title":"Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: a French experience","volume":"5","author":"Grassin","year":"2010","journal-title":"J Thorac Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdu527_bb0135","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.lungcan.2009.03.031","article-title":"Efficacy of chemotherapy with carboplatin and paclitaxel for unresectable thymic carcinoma","volume":"67","author":"Igawa","year":"2010","journal-title":"Lung Cancer"},{"issue":"8","key":"10.1093\/annonc\/mdu527_bb0140","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/jjco\/hyr089","article-title":"Combination chemotherapy with carboplatin and paclitaxel for advanced thymic cancer","volume":"41","author":"Furugen","year":"2011","journal-title":"Jpn J Clin Oncol"},{"issue":"suppl","key":"10.1093\/annonc\/mdu527_bb0145","first-page":"428s","article-title":"A phase II study of carboplatin plus paclitaxel in advanced thymoma or thymic carcinoma: E1C99","volume":"26","author":"Lemma","year":"2008","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"10.1093\/annonc\/mdu527_bb0150","article-title":"A multicenter prospective study of carboplatin and paclitaxel for advanced thymic carcinoma: West Japan Oncology Group 4207L","volume":"31","author":"Takeda","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu527_bb0155","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.lungcan.2011.05.013","article-title":"Cisplatin and irinotecan combination chemotherapy for advanced thymic carcinoma: evaluation of efficacy and toxicity","volume":"74","author":"Okuma","year":"2011","journal-title":"Lung Cancer"},{"issue":"suppl","key":"10.1093\/annonc\/mdu527_bb0160","article-title":"Key components of chemotherapy for thymoma and thymic carcinoma: anthracycline-, carboplatin-, or cisplatin-based chemotherapy","volume":"32","author":"Okuma","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu527_bb0165","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1093\/annonc\/mdp483","article-title":"Preliminary results of phase II study of capecitabine and gemcitabine (CAP-GEM) in patients with metastatic pretreated thymic epithelial tumors (TETs)","volume":"21","author":"Palmieri","year":"2010","journal-title":"Ann Oncol"},{"issue":"suppl","key":"10.1093\/annonc\/mdu527_bb0170","first-page":"5s","article-title":"Capecitabine plus gemcitabine in thymic epithelial tumors: final analysis of a phase II trial","volume":"32","author":"Buonerba","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu527_bb0175","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1056\/NEJM200406173502523","article-title":"Thymic carcinoma with overexpression of mutated KIT and the response to imatinib","volume":"350","author":"Strobel","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdu527_bb0180","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s12032-008-9100-0","article-title":"Response to sorafenib in cisplatin resistant thymic carcinoma: a case report","volume":"26","author":"Li","year":"2009","journal-title":"Med Oncol"},{"key":"10.1093\/annonc\/mdu527_bb0185","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1200\/JCO.2006.08.8963","article-title":"Dasatinib induces a response in malignant thymoma","volume":"24","author":"Chuah","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu527_bb0190","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/annonc\/mdn388","article-title":"Response of malignant thymoma to erlotinib","volume":"19","author":"Christodoulou","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdu527_bb0195","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S1470-2045(07)70141-9","article-title":"Response of thymoma to cetuximab","volume":"8","author":"Farina","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdu527_bb0200","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.lungcan.2006.01.009","article-title":"Thymic carcinoma with epidermal growth factor receptor gene mutations","volume":"52","author":"Yamaguchi","year":"2006","journal-title":"Lung Cancer"},{"issue":"8","key":"10.1093\/annonc\/mdu527_bb0205","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/ng.3016","article-title":"A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors","volume":"46","author":"Petrini","year":"2014","journal-title":"Nat Genet"},{"issue":"7","key":"10.1093\/annonc\/mdu527_bb0210","doi-asserted-by":"crossref","first-page":"e351","DOI":"10.1038\/cddis.2012.92","article-title":"Copy number aberrations of BCL2 and CDKN2A\/B identified by array-CGH in thymic epithelial tumors","volume":"3","author":"Petrini","year":"2012","journal-title":"Cell Death Dis"},{"issue":"2","key":"10.1093\/annonc\/mdu527_bb0215","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.lungcan.2014.08.020","article-title":"Genetic profiling of thymic carcinoma using targeted next-generation sequencing","volume":"86","author":"Shitara","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1093\/annonc\/mdu527_bb0220","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2005.23.16_suppl.7068","article-title":"Phase II study of gefitinib treatment in advanced thymic malignancies","volume":"23","author":"Kurup","year":"2005","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"10.1093\/annonc\/mdu527_bb0225","article-title":"A Phase II trial of erlotinib plus bevacizumab in patients with recurrent thymoma or thymic carcinoma","volume":"15","author":"Bedano","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu527_bb0230","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1097\/JTO.0b013e3181b6be57","article-title":"Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas","volume":"4","author":"Giaccone","year":"2009","journal-title":"J Thorac Oncol"},{"issue":"suppl","key":"10.1093\/annonc\/mdu527_bb0235","article-title":"Imatinib for the treatment of thymic carcinoma","volume":"26","author":"Salter","year":"2008","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdu527_bb0240","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00280-011-1690-0","article-title":"Imatinib mesylate in thymic epithelial malignancies","volume":"69","author":"Palmieri","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1093\/annonc\/mdu527_bb0245","doi-asserted-by":"crossref","first-page":"5834","DOI":"10.1158\/1078-0432.CCR-07-1118","article-title":"Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors","volume":"13","author":"Haluska","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1093\/annonc\/mdu527_bb0250","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1470-2045(13)70596-5","article-title":"Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial","volume":"15","author":"Rajan","year":"2014","journal-title":"Lancet Oncol"},{"issue":"suppl","key":"10.1093\/annonc\/mdu527_bb0255","first-page":"177s","article-title":"A phase I dose escalation and pharmacokinetic (PK) study of intravenous aflibercept (VEGF trap) plus docetaxel (D) in patients (pts) with advanced solid tumors: preliminary results","volume":"26","author":"Isambert","year":"2008","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"10.1093\/annonc\/mdu527_bb0260","first-page":"5s","article-title":"Phase II trial of sunitinib in patients with thymic epithelial tumors (TET)","volume":"32","author":"Thomas","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu527_bb0265","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/annonc\/mdq313","article-title":"Phase I trial of SU14813 in patients with advanced solid malignancies","volume":"22","author":"Fiedler","year":"2011","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdu527_bb0270","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1080\/02841860802495362","article-title":"Motesanib diphosphate (AMG 706), an oral angiogenesis inhibitor, demonstrates clinical efficacy in advanced thymoma","volume":"48","author":"Azad","year":"2009","journal-title":"Acta Oncol"},{"key":"10.1093\/annonc\/mdu527_bb0275","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1002\/cncr.10374","article-title":"Somatostatin analogs and prednisone in advanced refractory thymic tumors","volume":"94","author":"Palmieri","year":"2002","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdu527_bb0280","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1200\/JCO.2004.02.047","article-title":"Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group Phase II trial","volume":"22","author":"Loehrer","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu527_bb0285","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/COC.0b013e318209a8f8","article-title":"Efficacy and tolerability of long lasting octreotide in the treatment of thymic tumours: results of a pilot trial","volume":"35","author":"Longo","year":"2012","journal-title":"Am J Clin Oncol"},{"key":"10.1093\/annonc\/mdu527_bb0290","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1158\/1078-0432.CCR-07-1786","article-title":"A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors","volume":"14","author":"Steele","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"suppl","key":"10.1093\/annonc\/mdu527_bb0295","article-title":"Phase II study of the histone deacetylase inhibitor belinostat in thymic malignancies","volume":"27","author":"Giaccone","year":"2009","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"10.1093\/annonc\/mdu527_bb0300","first-page":"5s","article-title":"A phase II study of milciclib (PHA-848125AC) in patients (pts9 with thymic carcinoma (TC)","volume":"32","author":"Besse","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu527_bb0305","unstructured":"HAWakeleeMAGubensMBurnsA phase II study of saracatinib (AZD0530), a SRC inhibitor, administered orally daily to patients with advanced thymic malignancies. In: Presented at International Thymic Malignancy Group Conference. New York, NY. 5\u20136 May 2010."},{"issue":"suppl","key":"10.1093\/annonc\/mdu527_bb0310","first-page":"5s","article-title":"Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy","volume":"32","author":"Zucali","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu527_bb0315","doi-asserted-by":"crossref","first-page":"6790","DOI":"10.1158\/1078-0432.CCR-09-0644","article-title":"Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas","volume":"15","author":"Girard","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdu527_bb0320","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1365-2559.1993.tb01181.x","article-title":"Expression of epidermal and nerve growth factor receptors in human thymus and thymomas","volume":"23","author":"Pescarmona","year":"1993","journal-title":"Histopathology"},{"key":"10.1093\/annonc\/mdu527_bb0325","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1136\/jcp.48.5.447","article-title":"Oncogene proteins and proliferation antigens in thymomas: increased expression of epidermal growth factor receptor and Ki67 antigen","volume":"48","author":"Gilhus","year":"1995","journal-title":"J Clin Pathol"},{"key":"10.1093\/annonc\/mdu527_bb0330","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00432-001-0319-9","article-title":"Epidermal growth factor receptor expression in invasive thymoma","volume":"128","author":"Henley","year":"2002","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1093\/annonc\/mdu527_bb0335","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1093\/jjco\/hyl028","article-title":"Expression and mutation statuses of epidermal growth factor receptor in thymic epithelial tumors","volume":"36","author":"Suzuki","year":"2006","journal-title":"Jpn J Clin Oncol"},{"key":"10.1093\/annonc\/mdu527_bb0340","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.canlet.2006.07.003","article-title":"Mutational status of the epidermal growth factor receptor (EGFR) gene in thymomas and thymic carcinomas","volume":"248","author":"Meister","year":"2007","journal-title":"Cancer Lett"},{"key":"10.1093\/annonc\/mdu527_bb0345","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.lungcan.2008.03.013","article-title":"Mutational status of EGFR and KIT in thymoma and thymic carcinoma","volume":"62","author":"Yoh","year":"2008","journal-title":"Lung Cancer"},{"key":"10.1093\/annonc\/mdu527_bb0350","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1097\/JTO.0b013e3181d86a30","volume":"5","author":"Aisner","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1093\/annonc\/mdu527_bb0355","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/cncr.20811","article-title":"Protein expression and gene amplification of epidermal growth factor receptor in thymomas","volume":"103","author":"Ionescu","year":"2005","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdu527_bb0360","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2741\/2098","article-title":"Cetuximab is an active treatment of metastatic and chemorefractory thymoma","volume":"12","author":"Palmieri","year":"2007","journal-title":"Front Biosci"},{"key":"10.1093\/annonc\/mdu527_bb0365","doi-asserted-by":"crossref","first-page":"S291","DOI":"10.1097\/JTO.0b013e3181f209b9","article-title":"Thymic tumors. Relevant molecular data in the clinic","volume":"5","author":"Girard","year":"2010","journal-title":"J Thorac Oncol"},{"issue":"5","key":"10.1093\/annonc\/mdu527_bb0370","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1586\/era.12.29","article-title":"Chemotherapy and targeted agents for thymic malignancies","volume":"12","author":"Girard","year":"2012","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1093\/annonc\/mdu527_bb0375","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1097\/JTO.0b013e3181e392a8","article-title":"Insulin-like growth factor-1 receptor expression in thymic malignancies","volume":"5","author":"Girard","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1093\/annonc\/mdu527_bb0380","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.1002\/cncr.25367","article-title":"Insulinlike growth factor-1 receptor and phosphorylated AKT-serine 473 expression in 132 resected thymomas and thymic carcinomas","volume":"16","author":"Zucali","year":"2010","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdu527_bb0385","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.aanat.2007.05.003","article-title":"Immunohistochemical expression of vascular endothelial growth factor A (VEGF), and its receptors (VEGFR1, 2) in normal and pathologic conditions of the human thymus","volume":"190","author":"Cimpean","year":"2008","journal-title":"Ann Anat"},{"key":"10.1093\/annonc\/mdu527_bb0390","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1067\/mtc.2002.124389","article-title":"Correlation between tumor angiogenesis and invasiveness in thymic epithelial tumors","volume":"124","author":"Tomita","year":"2002","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1093\/annonc\/mdu527_bb0395","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1007\/s005950170021","article-title":"Elevated serum vascular endothelial growth factor and basic fibroblast growth factor levels in patients with thymic epithelial neoplasms","volume":"31","author":"Sasaki","year":"2001","journal-title":"Surg Today"},{"key":"10.1093\/annonc\/mdu527_bb0400","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/JTO.0b013e3181a52e25","article-title":"Long lasting response to the multikinase inhibitor bay 43\u20139006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma","volume":"4","author":"Bisagni","year":"2009","journal-title":"J Thorac Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdu527_bb0405","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s11523-012-0235-8","article-title":"Long lasting efficacy of sorafenib in a heavily pretreated patient with thymic carcinoma","volume":"7","author":"Neuhaus","year":"2012","journal-title":"Target Oncol"},{"key":"10.1093\/annonc\/mdu527_bb0410","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1210\/endo.140.1.6398","article-title":"In vitro characterization of somatostatin receptors in the human thymus and effects of somatostatin and octreotide on cultured thymic epithelial cells","volume":"140","author":"Ferone","year":"1999","journal-title":"Endocrinology"},{"key":"10.1093\/annonc\/mdu527_bb0415","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ejcts.2005.06.034","article-title":"Expression of neurotrophin receptors in surgically resected thymic epithelial tumors","volume":"28","author":"Kim","year":"2005","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1093\/annonc\/mdu527_bb0420","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/(SICI)1097-0215(19971127)73:5<639::AID-IJC5>3.0.CO;2-Y","article-title":"p16INK4, pRB, p53 and cyclin D1 expression and hypermethylation of CDKN2 gene in thymoma and thymic carcinoma","volume":"73","author":"Hirabayashi","year":"1997","journal-title":"Int J Cancer"},{"key":"10.1093\/annonc\/mdu527_bb0425","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.lungcan.2008.07.015","article-title":"Aberrant methylation of tumour-related genes in thymic epithelial tumours","volume":"64","author":"Hirose","year":"2009","journal-title":"Lung Cancer"},{"key":"10.1093\/annonc\/mdu527_bb0430","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/labinvest.3700292","article-title":"Malignant transformation of thymoma in recipient rats by heterotopic thymus transplantation from HTLV-I transgenic rats","volume":"85","author":"Tsuji","year":"2005","journal-title":"Lab Invest"},{"key":"10.1093\/annonc\/mdu527_bb0435","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1002\/cncr.21433","article-title":"Long term disease-free survival of patients with radically resected thymomas: relevance of cell-cycle protein expression","volume":"104","author":"Mineo","year":"2005","journal-title":"Cancer"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419314899?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419314899?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/26\/5\/838\/10767251\/mdu527.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T07:48:39Z","timestamp":1624520919000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419314899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":86,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S0923753419314899"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdu527","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]}}}